AbbVie Inc.: Beat — EPS $3.82, Revenue $17.4B
Earnings BeatQ3 2026 · Pre-market
Did AbbVie Inc. (ABBV) beat earnings today?
Yes, AbbVie Inc. (ABBV) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+1.33% surprise
$3.82Actual
Expected: $3.77
vs. year ago +105.4%
Total Revenue+0.31% surprise
$17.4BActual
Expected: $17.35B
vs. year ago +10.3%
Released Oct 30 · 7:46 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Net Revenues | $17.40B | $15.78B | +10.3% |
| Revenue detail — reported lines | |||
| └─Immunology | $9.16B | - | +16.3% |
| └─Skyrizi | $5.78B | - | +22.7% |
| └─Rinvoq | $2.71B | - | +23.9% |
| └─Humira | $683.00M | - | -31.2% |
| └─Neuroscience | $3.39B | - | +19.4% |
| └─Vraylar | $1.07B | - | +14.3% |
| └─Botox Therapeutic | $1.08B | - | +9.8% |
| └─Ubrelvy | $492.00M | - | +26.9% |
| └─Qulipta | $398.00M | - | +38.2% |
| └─Vyalev | $286.00M | - | - |
| └─Other Neuroscience | $108.00M | - | -23.9% |
| └─Oncology | $1.70B | - | +0.8% |
| └─Venclexta | $803.00M | - | +10.7% |
| └─Imbruvica | $522.00M | - | -26.1% |
| └─Elahere | $224.00M | - | +31.0% |
| └─Epkinly | $108.00M | - | +57.7% |
| └─Other Oncology | $39.00M | - | - |
| └─Aesthetics | $1.18B | - | -1.4% |
| └─Botox Cosmetic | $669.00M | - | +4.9% |
| └─Juvederm Collection | $222.00M | - | -11.9% |
| └─Other Aesthetics | $285.00M | - | -6.0% |
| └─Other Key Products | $965.00M | - | -4.1% |
| └─Mavyret | $265.00M | - | -15.1% |
| └─Creon | $361.00M | - | -2.2% |
| └─Linzess | $339.00M | - | +4.2% |
| Net earnings attributable to AbbVie Inc. | $4.22B | $186.00M | +2167.7% |
| GAAP Diluted EPS | $2.37 | $0.10 | +2270.0% |
| Adjusted Diluted EPS | $3.82 | $1.86 | +105.4% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY2026 Outlook | Expected |
|---|---|---|---|
| Adjusted Diluted EPS | — | $13.95-$13.99 (prev. $13.76-$13.96) | $13.95Beat +0.14% |
Business Highlights
- ➤Completed the Apogee Therapeutics acquisition, adding immunology assets targeting inflammatory and immunological diseases.
- ➤FDA approved Skyrizi SC induction for moderately to severely active Crohn's disease.
- ➤Submitted an EMA application for Skyrizi SC induction in adult Crohn's disease.
- ➤Phase 3 INTREPID lutikizumab study met its primary endpoint in hidradenitis suppurativa.
- ➤Presented 20 IBD research presentations at 2026 UEG Week.
- ➤FDA approved Juvmo for adults with Parkinson's disease.
- ➤Submitted an FDA BLA for etentamig in relapsed/refractory multiple myeloma.
- ➤FDA granted two Breakthrough Therapy Designations for Temab-A.
- ➤FDA accepted the supplemental BLA for Botox Cosmetic in masseter muscle prominence.
- ➤Advanced ABBV-295 into Phase 2 development for chronic weight management.
- ➤Agreed with Valkai to apply AI across targeted clinical-development areas.
- ➤Formed a multi-year strategic relationship with Iambic for small-molecule discovery and development.
- ➤Increased quarterly cash dividend to $1.82 per share, payable February 16, 2027.
Management Commentary
Robert A. Michael, chairman and chief executive officer, AbbVie
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”